LNTH Price Prediction Next Week
Technical Analysis: Based on the latest market data, LNTH is showing signs of a potential reversal after recent decline. The stock closed at $83.41 on February 18, 2025, with a significant 4.34% gain during regular trading hours.
Key technical indicators suggest:
- RSI-14 at 38.66 indicates oversold conditions
- MACD is showing bearish momentum with -2.90
- Stock is trading below its 200-day SMA ($94.80), indicating long-term bearish trend
- Currently trading near the lower Bollinger Band ($73.50), suggesting potential bounce
News Impact: Recent significant news affecting LNTH:
- Strategic acquisition of Evergreen Theragnostics for $250M upfront with potential milestone payments up to $752.5M
- Leerink Partners maintains Buy rating, citing enhanced radiopharmaceutical infrastructure
- Management maintains FY24 adjusted EPS guidance of $6.65-$6.70
Price Prediction for Next Week: Based on Fibonacci levels and technical indicators:
- Resistance levels: $86.16 (pivot), $91.46 (R1), $94.73 (R2)
- Support levels: $80.85 (S1), $77.58 (S2)
Expected price range: $82-88
- Base case (60% probability): Stock consolidates between $83-86
- Bullish case (25% probability): Breaks above $86.16 to test $91.46
- Bearish case (15% probability): Drops to test S1 at $80.85
Trading Recommendation: BUY
- Entry point: Current levels ($83.85)
- Stop loss: $80.85 (S1 level)
- Target: $91.46 (R1 level)
Rationale:
- Oversold technical conditions suggest potential bounce
- Strong analyst support post-acquisition announcement
- Positive momentum from recent 4.34% gain
- Trading near support levels provides favorable risk-reward
LNTH Similar Chart Price Prediction
The price of LNTH is predicted to go up -21.09%, based on the high correlation periods with CDXS. The similarity of these two price pattern on the periods is 95.79%.
LNTH
CDXS
Down: -21.09%Similarity: 95.79%
LNTH Revenue Forecast
LNTH EPS Forecast
LNTH FAQs
What is bull’s view on LNTH?
What is bear's view on LNTH?
What is LNTH revenue forecast for next quarter？
What is LNTH eps forecast for next quarter？
LNTH Analyst's Forecast
Paul Choi
Goldman Sachs
Strong Buy
2024-12-18
Price Target
$143
Upside
+56.88%
Goldman Sachs analyst Paul Choi initiated coverage of Lantheus with a Buy rating and $143 price target. The firm says concerns about Pylarify growth overdone as the company has "best-in-class" infrastructure for exposure to the "attractive" theranostics and Alzheimer's thematics. Goldman estimates Lantheus shares offer at an attractive entry point at these levels as Street estimates are underestimating Pylarify growth, the analyst tells investors in a research note. The firm believes Alzheimer's disease diagnostics could emerge as meaningful drivers with an opportunity to unlock an over $1.5B market opportunity.
Richard Newitter
Truist Securities
Strong Buy
2024-11-08
Price Target
$135 → $120
Upside
+37.14%
